BAJAJ BROKING

Notification close image
No new Notification messages
card image
Anlon Healthcare Ltd IPO is open
Apply for the Anlon Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

539730

FREDUN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Fredun Pharmaceuticals Limited Share Price Update

As of the latest trading session, Fredun Pharmaceuticals Limited share price is currently at ₹ 1136, which is down by ₹ -32.44 from its previous closing. Today, the stock has fluctuated between ₹ 1136.00 and ₹ 1180.00. Over the past year, Fredun Pharmaceuticals Limited has achieved a return of 46.45 %. In the last month alone, the return has been 26.75 %. Read More...

Investment Returns

Over 1 Month 26.75% Over 3 Months 58.17% Over 6 Months 71.79% Over 1 Year 46.45%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Fredun Pharmaceuticals Limited fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    539.30

  • P/E Ratio (TTM)

    23.53

  • Beta

    0.41

  • Book Value / share

    299.47

  • Return on equity

    14.34%

  • EPS (TTM)

    49.65

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    6.77

info icon alternate text

Fredun Pharmaceuticals Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 119.40
Operating Expense 110.81
Net Profit 6.77
Net Profit Margin (%) 5.67
Earnings Per Share (EPS) 14.33
EBITDA 16.99
Effective Tax Rate (%) 25.11
Particulars MAR 2025 (Values in Cr)
Revenue 165.44
Operating Expense 159.37
Net Profit 7.07
Net Profit Margin (%) 4.27
Earnings Per Share (EPS) 14.98
EBITDA 17.43
Effective Tax Rate (%) 12.06
Particulars DEC 2024 (Values in Cr)
Revenue 101.84
Operating Expense 95.56
Net Profit 5.33
Net Profit Margin (%) 5.23
Earnings Per Share (EPS) 11.29
EBITDA 13.21
Effective Tax Rate (%) 25.24
Particulars SEP 2024 (Values in Cr)
Revenue 106.89
Operating Expense 99.78
Net Profit 4.27
Net Profit Margin (%) 3.99
Earnings Per Share (EPS) 9.05
EBITDA 13.95
Effective Tax Rate (%) 43.53
Particulars JUN 2024 (Values in Cr)
Revenue 77.54
Operating Expense 73.28
Net Profit 4.13
Net Profit Margin (%) 5.32
Earnings Per Share (EPS) 8.79
EBITDA 10.48
Effective Tax Rate (%) 25.18
Particulars MAR 2025 (Values in Cr)
Revenue 451.71
Operating Expense 428.00
Net Profit 20.81
Net Profit Margin (%) 4.60
Earnings Per Share (EPS) 44.83
EBITDA 55.10
Effective Tax Rate (%) 26.38
Particulars MAR 2024 (Values in Cr)
Revenue 346.58
Operating Expense 327.62
Net Profit 15.62
Net Profit Margin (%) 4.50
Earnings Per Share (EPS) 33.32
EBITDA 38.90
Effective Tax Rate (%) 27.17
Particulars MAR 2023 (Values in Cr)
Revenue 274.34
Operating Expense 258.99
Net Profit 10.81
Net Profit Margin (%) 3.94
Earnings Per Share (EPS) 22.93
EBITDA 29.59
Effective Tax Rate (%) 38.26
Particulars MAR 2022 (Values in Cr)
Revenue 221.74
Operating Expense 217.48
Net Profit 6.34
Net Profit Margin (%) 2.85
Earnings Per Share (EPS) 14.29
EBITDA 15.43
Effective Tax Rate (%) 26.27
Particulars MAR 2021 (Values in Cr)
Revenue 131.55
Operating Expense 130.92
Net Profit 2.01
Net Profit Margin (%) 1.52
Earnings Per Share (EPS) 5.05
EBITDA 9.37
Effective Tax Rate (%) 37.07
Particulars MAR 2024 (Values in Cr)
Book Value / Share 255.15
ROE % 14.34
ROCE % 16.95
Total Debt to Total Equity 0.88
EBITDA Margin 11.17
Particulars MAR 2023 (Values in Cr)
Book Value / Share 194.27
ROE % 13.15
ROCE % 17.43
Total Debt to Total Equity 0.85
EBITDA Margin 10.78
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.07
ROE % 11.41
ROCE % 12.90
Total Debt to Total Equity 0.83
EBITDA Margin 6.91
Particulars MAR 2021 (Values in Cr)
Book Value / Share 107.96
ROE % 4.76
ROCE % 9.34
Total Debt to Total Equity 0.88
EBITDA Margin 7.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 103.57
ROE % 4.73
ROCE % 10.16
Total Debt to Total Equity 0.67
EBITDA Margin 7.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.35
Total Assets 307.59
Total Liabilities 307.59
Total Equity 121.47
Share Outstanding 4699162
Price to Book Ratio 2.81
Return on Assets (%) 5.07
Return on Capital (%) 6.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.43
Total Assets 257.27
Total Liabilities 257.27
Total Equity 96.37
Share Outstanding 4532272
Price to Book Ratio 4.00
Return on Assets (%) 4.20
Return on Capital (%) 5.91
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 186.98
Total Liabilities 186.98
Total Equity 68.06
Share Outstanding 4432643
Price to Book Ratio 5.98
Return on Assets (%) 3.38
Return on Capital (%) 5.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.12
Total Assets 161.61
Total Liabilities 161.61
Total Equity 43.07
Share Outstanding 3989634
Price to Book Ratio 4.29
Return on Assets (%) 1.24
Return on Capital (%) 2.44
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.05
Total Assets 141.37
Total Liabilities 141.37
Total Equity 41.32
Share Outstanding 3989634
Price to Book Ratio 1.13
Return on Assets (%) 1.34
Return on Capital (%) 2.5
Particulars MAR 2024 (Values in Cr)
Net Income 15.62
Cash from Operations -0.43
Cash from Investing -7.63
Cash from Financing 5.99
Net change in Cash -2.08
Free Cash Flow 7.20
Particulars MAR 2023 (Values in Cr)
Net Income 10.75
Cash from Operations -14.40
Cash from Investing -9.40
Cash from Financing 25.17
Net change in Cash 1.36
Free Cash Flow -4.91
Particulars MAR 2022 (Values in Cr)
Net Income 6.31
Cash from Operations -2.38
Cash from Investing -4.14
Cash from Financing 7.46
Net change in Cash 0.94
Free Cash Flow 1.90
Particulars MAR 2021 (Values in Cr)
Net Income 2.01
Cash from Operations 0.16
Cash from Investing -1.38
Cash from Financing -0.71
Net change in Cash -1.93
Free Cash Flow 1.55
Particulars MAR 2020 (Values in Cr)
Net Income 2.34
Cash from Operations -10.61
Cash from Investing -1.49
Cash from Financing 13.72
Net change in Cash 1.59
Free Cash Flow -9.12
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.62 13.31 1.78 249.98 30.00 / 69.75
BLISS GVS PHARMA LTD 162.50 16.07 1.63 1714.33 105.05 / 190.65
CIPLA LTD 1579.85 23.66 4.09 127613.03 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 327.35 9.22 2.65 963.42 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.62 17.73 5.15 249.98 30.00 / 69.75
AMRUTANJAN HEALTH CARE LTD. 703.70 37.31 6.22 2034.44 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8014.90 94.75 26.01 20037.25 6222.35 / 10653.05
BLISS GVS PHARMA LTD 162.50 24.29 1.61 1714.33 105.05 / 190.65

Fredun Pharmaceuticals Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1142.15 -2.25 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 1173.70
  • 26 Days 1050.90
  • 10 Days 1132.70
  • 50 Days 971.80
  • 12 Days 1119.70
  • 100 Days 883.10
  • 20 Days 1077.10
  • 200 Days 823.80
1214.12 PIVOT

First Support

1109.23

First Resistance

1273.33

Second Support

1050.02

Second Resistance

1378.22

Third Support

945.13

Third Resistance

1437.43

RSI

64.52

ADX

57.49

MACD

68.79

Williams % R

-51.33

Commodity Channel Index (CCI)

166.50

Date

2025-08-26

Week

21464.00

Same Day

23669.00

Month

19303.00

1 Year

0.42

3 Year

0.63

Over 1 Month

26.75%

down

Over 1 Year

46.45%

down

Over 3 Months

58.17%

down

Over 3 Years

-1.39%

down

Over 6 Months

71.79%

down

Over 5 Years

39.63%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Fredun Pharmaceuticals Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

Fredun Pharmaceuticals Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
23 Sep 2024 0.7 Final 23 Sep 2024 Equity shares
22 Sep 2023 0.7 Final 22 Sep 2023 Equity shares
16 Sep 2021 0.7 Final 18 Sep 2021 Equity shares
16 Sep 2019 0.65 Final 18 Sep 2019 Equity shares
18 Sep 2018 0.6 Final 21 Sep 2018 Equity shares
20 Sep 2017 0.6 Final 22 Sep 2017 Equity shares
11 Apr 2016 0.6 Interim 13 Apr 2016 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Fredun Pharmaceuticals Limited Share Price

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL.

The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems.

The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind.

In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden.

Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka.

In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category.

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Fredun Pharmaceuticals Ltd?

Answer Field

Fredun Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 1,142.15 as on Aug 28 2025 03:29 PM.

What is the Market Cap of Fredun Pharmaceuticals Ltd Share?

Answer Field

The market cap of Fredun Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 539.30 as on Aug 28 2025 03:29 PM.

What is the 52 Week High and Low of Fredun Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 1,329.00 and ₹ 635.00.

What is 1 year return for Fredun Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 46.45%.

What is the P/E Ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Aug 28 2025 03:29 PM the price-to-earnings (PE) ratio for Fredun Pharmaceuticals Ltd share is 23.53.

What is the PB ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Aug 28 2025 03:29 PM, the price-to-book (PB) ratio for Fredun Pharmaceuticals Ltd share is 299.47.

How to Buy Fredun Pharmaceuticals Ltd Share?

Answer Field

You can trade in Fredun Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Fredun Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Fredun Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Fredun Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91